Cellectis (CLLS) Receivables (2013 - 2026)
Cellectis (CLLS) posted quarterly Receivables of $12.7 million for Q1 2026, down 44.56% year-over-year from $23.0 million in Q1 2025, and down 42.58% quarter-over-quarter from $22.2 million in Q4 2025.
Analysis
Cellectis (CLLS) Receivables (2013 - 2026) Analysis & Trends
Cellectis' Receivables history runs 14 years deep, the most recent figure standing at $12.7 million for Q1 2026.
- In Q1 2026, Receivables fell 44.56% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $12.7 million (down 44.56% YoY), while the FY2025 annual figure was $22.2 million, up 4.53% from the prior year.
- Receivables for Q1 2026 stood at $12.7 million, down from $22.2 million in the prior quarter.
- The five-year high for Receivables was $39.1 million in Q1 2024, with the low at $12.7 million in Q1 2026.
- The 5-year median for Receivables is $21.5 million (2023), against an average of $22.1 million.
- The sharpest annual moves came in 2022 and 2024: Receivables sank 48.52% in 2022, then soared 102.1% in 2024.
- Cellectis' Receivables stood at $15.3 million in 2022, then soared by 40.61% to $21.5 million in 2023, then retreated by 1.09% to $21.2 million in 2024, then rose by 4.53% to $22.2 million in 2025, then slumped by 42.58% to $12.7 million in 2026.
- Business Quant data shows CLLS's Receivables at $12.7 million in Q1 2026, $22.2 million in Q4 2025, and $24.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 5.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.08 Mn |
| Mar 31, 2026 | 5.15 Mn |
| Dec 31, 2025 | 14.40 Mn |
| Sep 30, 2025 | 8.06 Mn |
| Jun 30, 2025 | 8.78 Mn |
| Mar 31, 2025 | 7.87 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 11.18 Mn |
| Jun 30, 2024 | 9.74 Mn |
| Mar 31, 2024 | 16.04 Mn |
| Dec 31, 2023 | 569,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Jun 30, 2023 | 422,000.00 |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 772,000.00 |
| Sep 30, 2022 | 802,000.00 |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 21.84 Mn |
| Dec 31, 2021 | 20.36 Mn |
| Sep 30, 2021 | 349,000.00 |